We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
KAMRAB (Link Medical Products Pty Ltd T/A Link Pharmaceuticals)
Product name
KAMRAB
Date registered
Evaluation commenced
Decision date
Approval time
181 (175 working days)
Active ingredients
rabies immunoglobulin
Registration type
NCE/NBE
Indication
KAMRAB (solution for injection) is rabies immunoglobulin indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KAMRAB should be administered concurrently with a full course of rabies vaccine.
- Do not administer additional (repeat) doses of KAMRAB once vaccine treatment has been initiated, since this may interfere with the immune response to the rabies vaccine.
- Do not administer KAMRAB to patients with a history of a complete pre-exposure or post-exposure vaccination regimen and confirmed adequate rabies antibody titre.